Online Disruptive 10-K/A 3 Apr 17 2016 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2017	Jun. 30, 2016
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Trading Symbol	odt
Entity Registrant Name	ONLINE DISRUPTIVE TECHNOLOGIES, INC.
Entity Central Index Key	1,498,380
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		114,180,828
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Public Float			$ 13,480,878
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and Cash Equivalents	$ 452,376	$ 1,205,928
Prepaid expenses	1,687	3,532
VAT Receivable	28,907	22,208
Total Current Assets	482,970	1,231,668
Restricted cash	20,857	12,814
Fixed Assets	55,444	58,321
Total Assets	559,271	1,302,803
Current Liabilities
Accounts Payable	61,356	54,674
Accrued Liabilities	115,650	72,117
Total Current Liabilities	177,006	126,791
Convertible debentures	729,475	380,199
Total Liabilities	906,481	506,990
(DEFICIT)/EQUITY
Authorized: 20,000,000 Preferred Shares, par value $0.001 500,000,000 Common Shares, par value $0.001 Issued and outstanding: Nil Preferred Shares 114,180,828 Common Shares (December 31, 2015: 98,979,174 Common Shares)	98,581	83,379
Additional Paid-in Capital	9,568,625	8,715,819
Accumulated Other Comprehensive Loss	(88,180)	(88,720)
Deficit	(9,982,269)	(8,026,578)
(Deficit)/Equity Attributable to Shareholders of the Company	(403,243)	683,900
Non-Controlling Interests	56,033	111,913
Total (Deficit)/Equity	(347,210)	795,813
Total Liabilities and (Deficit)/Equity	$ 559,271	$ 1,302,803

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Issued	114,180,828	98,979,174
Common Stock, Shares, Outstanding	114,180,828	98,979,174

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
General and Administrative Expenses
Accounting Fees	$ 30,000	$ 28,250
Audit & Tax Fees	68,851	54,117
Bank Fees	538	727
Consulting Fees	388,018	372,455
Filing and Transfer Agent Fees	14,208	11,936
Insurance Expense	46,986	48,373
Legal Fees	38,699	57,728
Marketing Expense	0	32,383
Office and Miscellaneous Expense	74,198	89,062
Payroll Expense	45,156	46,785
Rent Expense	3,231	980
Research and Development Expense	1,327,758	1,615,745
Travel Expenses	14,655	8,633
Total General and Administrative Expenses	2,052,298	2,367,174
Other Expense
Interest Accretion	176,382	182,448
Interest Expense	468	2,415
Foreign Currency Loss	2,873	37,197
Net Loss for the year	(2,232,021)	(2,589,234)
Other Comprehensive Income
Currency translation adjustments	540	5,245
Comprehensive Loss for the year	(2,231,481)	(2,583,989)
Net (Loss) attributable to:
Common Stockholders	(1,955,691)	(2,141,671)
Non-Controlling Interests	(276,330)	(447,563)
Net loss for the year	(2,232,021)	(2,589,234)
Net Comprehensive Loss Attributable to:
Common Stockholders	(1,955,218)	(2,137,333)
Non-Controlling Interests	(276,263)	(446,656)
Comprehensive Income (Loss) for the year	$ (2,231,481)	$ (2,583,989)
Basic and Diluted Net Loss per Common Share	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	107,753,316	91,672,129

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flow from Operating Activities
Net loss for the year	$ (2,232,021)	$ (2,589,234)
Adjustment for items not involving cash:
Stock-Based Compensation	312,187	486,592
Foreign exchange gain/loss	2,873	10,960
Depreciation - fixed assets	12,697	6,199
Debt settlement for Consulting Services	65,632	90,610
Interest accretion	176,382	182,448
Changes in non-cash working capital items:
Decrease(increase) in VAT receivable	(6,363)	166
(Decrease) in prepaid expense	1,845	2,277
Increase (decrease) in accounts payable and accrued liabilities	221,245	249,258
Net cash (used in) operating activities	(1,445,523)	(1,560,724)
Cash flow from financing activities
Common shares issued, net of issuance costs	784,250	1,800,812
Common shares issued by subsidiary	0	709,087
Net cash provided by financing activities	784,250	2,509,899
Cash flow from investing activities
Cash utilized in purchase of assets	(8,920)	(60,628)
Cash restricted for office lease and bank	(7,853)	(12,814)
Net cash provided by (used in) investing activities	(16,773)	(73,442)
Effects of exchange rate changes on cash and cash equivalents	(75,506)	340
Net Increase in cash and cash equivalents	(753,552)	876,073
Cash and cash equivalents, beginning of year	1,205,928	329,855
Cash and cash equivalents, end of year	452,376	1,205,928
Supplementary Information
Interest Paid	0	0
Income Taxes Paid	$ 0	$ 0

Consolidated Statements of (Def

Consolidated Statements of (Deficiency) Equity - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	(Deficit) [Member]	Total Common Shareholders (Deficiency)/Equity [Member]	Non-controlling Interest [Member]	Total
Beginning Balance at Dec. 31, 2014	$ 67,036	$ 5,144,387	$ (93,964)	$ (5,884,907)	$ (767,448)	$ 227,425	$ (540,023)
Beginning Balance (Shares) at Dec. 31, 2014	82,636,433
Shares issued for cash at $0.20 per share	$ 9,050	1,800,950			1,810,000		1,810,000
Shares issued for cash at $0.20 per share (Shares)	9,050,000
Shares issued for investment in Savicell at $0.16	$ 6,249	993,538			999,787		999,787
Shares issued for investment in Savicell at $0.16 (Shares)	6,248,672
Conversion of debt for shares	$ 463	55,146			55,609		55,609
Conversion of debt for shares (Shares)	462,890
Stock options exercised for Shares	$ 581	5,231			5,812		5,812
Stock options exercised for Shares (Shares)	581,179
Stock Option Expense		486,592			486,592		486,592
Gain/Loss on conversion of debt to options		852,418			852,418		852,418
Change in ownership of Savicell		(607,443)			(607,443)	332,051	(275,392)
Foreign currency translation adjustment			5,244		5,244		5,244
Share issuance cost		(15,000)			(15,000)		(15,000)
Net loss for the year				(2,141,671)	(2,141,671)	(447,563)	(2,589,234)
Ending Balance at Dec. 31, 2015	$ 83,379	8,715,819	(88,720)	(8,026,578)	683,900	111,913	795,813
Ending Balance (Shares) at Dec. 31, 2015	98,979,174
Shares issued for cash at $0.20 per share	$ 3,125	621,875			625,000		625,000
Shares issued for cash at $0.20 per share (Shares)	3,125,000
Shares issued for investment in Savicell at $0.16	$ 12,027	1,912,239			1,924,266		1,924,266
Shares issued for investment in Savicell at $0.16 (Shares)	12,026,654
Stock options exercised for Shares	$ 50	450			500		500
Stock options exercised for Shares (Shares)	50,000
Share subscriptions received		158,750			158,750		158,750
Stock Option Expense		312,187			312,187		312,187
Change in ownership of Savicell		(2,152,695)			(2,152,695)	220,450	(1,932,245)
Foreign currency translation adjustment			540		540		540
Net loss for the year				(1,955,691)	(1,955,691)	(276,330)	(2,232,021)
Ending Balance at Dec. 31, 2016	$ 98,581	$ 9,568,625	$ (88,180)	$ (9,982,269)	$ (403,243)	$ 56,033	$ (347,210)
Ending Balance (Shares) at Dec. 31, 2016	114,180,828

Nature of Operations and going

Nature of Operations and going concern	12 Months Ended
	Dec. 31, 2016
Nature of Operations and going concern [Text Block]	Note 1 - Nature of Operations and going concern Online Disruptive Technologies, Inc. (“ODT” or the “Company”) was incorporated on November 16, 2009 in the State of Nevada, U.S.A. The Company was in the business of operating websites with advertising revenue platforms. However, as described below, the Company changed its primary business focus to the development and commercialization of a biotechnology platform. The Company has limited operations that has had no revenues from inception to date. The Company has a December 31 year-end. Effective March 24, 2010, the Company acquired 100% of the issued and outstanding shares of RelationshipScoreboard.com Entertainment Inc. (“RS” or “RelationshipScoreboard.com”), a company incorporated on November 16, 2009 in the state of Nevada, U.S.A. in exchange for 16,000,000 shares of the Company’s common stock. Upon the completion of the acquisition, the former sole shareholder of RS held 89% of the Company’s issued and outstanding common stock. As a result, the transaction was accounted for as a reverse takeover transaction (“RTO”) for accounting purpose, as RS was deemed to be the acquirer, and these consolidated financial statements are a continuation of the financial statements of RS. On January 28, 2013, RelationshipScoreboard.com was closed and dissolved. The Company sold the website assets for $10 to an arm’s length individual and wrote off all supplier payables in the amount of $430. On April 23, 2012, the Company established an Israeli subsidiary named Savicell Diagnostic Ltd. (“Savicell”) with the intention of exploring business ventures in the biotechnology sector. On July 25, 2012, Savicell entered into a definitive licensing agreement with a division of the Tel Aviv University for the purpose of developing and commercializing a new technology relative to the early detection of various forms of disease. With the consummation of this transaction, the Company is now entirely focused on its biotechnology efforts. These consolidated financial statements have been prepared with the ongoing assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has a working capital balance of $305,964 as at December 31, 2016 (working capital balance 2015 –$1,104,876) and an accumulated deficit of $9,982,269. Furthermore, additional future losses are anticipated which raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The operations of the Company have primarily been funded by the sale of common shares and loans received. Continued operations of the Company are dependent on the Company’s ability to complete equity financings or to generate profitable operations in the future. Management’s plan in this regard is to secure additional funds through future equity financings. Such financings may not be available or may not be available on reasonable terms to the Company. Failure to obtain the ongoing support of its equity financings and creditors may make the going concern basis of accounting inappropriate, in which case the Company’s assets and liabilities would need to be recognized at their liquidation values. These consolidation financial statements do not include any adjustments relating to the recoverability and classification of recorded assets amounts and classification of liabilities that might arise from this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Significant Accounting Policies [Text Block]	Note 2 - Significant Accounting Policies a) Basis of Presentation These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) and are expressed in United States dollars, unless otherwise noted. All adjustments considered necessary for a fair presentation of financial position, results of operations and cash flows as at December 31, 2016 have been included. b) Principles of Consolidation These consolidated financial statements include the accounts of the Company and its 86.13% (December 31, 2015-77.00%) interest in Savicell. All significant intercompany accounts and transactions have been eliminated upon consolidation. c) Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred income tax assets and determination of useful lives of property, plant and equipment. d) Foreign Currency Translation The Company’s functional currency is the U.S. dollar. Transactions in other currencies are recorded in U.S. dollars at the rates of exchange prevailing when the transactions occur. Monetary assets and liabilities denominated in other currencies are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates. Exchange gains and losses are recorded in the statements of operations. The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). All transactions are recorded in NIS. Monetary assets and liabilities denominated in NIS are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates and expenses are translated at the average exchange rates. Gains and losses from such translations are included in stockholders’ equity, as a component of other comprehensive income. In the year ended 2013, Savicell’s functional currency was the U.S. dollar. During the year 2014, with the increased volume of transactions in the local currency, the management reassessed Savicell’s functional currency to NIS based on the change in facts and effective as of January 1, 2014. Such change is still appropriate in 2016. As a result of the functional currency change discussed above, a cumulative translation adjustment of $540 is included in accumulated other comprehensive income and will only be adjusted in the event of a full or partial disposition of the Company's investment in Savicell. e) Cash and Cash Equivalents Cash and cash equivalents consist entirely of readily available cash balances. There were no cash equivalents as of December 31, 2016 and 2015. f) Stock-based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized as expense in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. Share-based payments issued to non-employees are recorded at their fair values at each reporting date, as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on a straight-line basis. g) Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, deferred tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply when the asset is realized or the liability is settled. The effect of a change in income tax rates on deferred tax liabilities and assets is recognized in income in the period in which the change occurs. Deferred tax assets are recognized to the extent that they are considered more likely than not to be realized. Per FASB ASC 740 “Income taxes” under the liability method, it is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At December 31, 2016, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company’s tax positions are recorded as Interest Expense. h) Comprehensive Income (Loss) The Company accounts for comprehensive income under the provisions of ASC Topic 220-10, Comprehensive Income - Overall, which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statements of Operations and Comprehensive Loss. i) Earnings (Loss) Per Share Basic loss per share is computed on the basis of the weighted average number of common shares outstanding during each period. Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the year ended December 31, 2016 and 2015 because the inclusion of such underlying shares would have had an anti-dilutive effect. j) Financial Instruments and Fair Value of Financial Instruments Fair Value of Financial Instruments – the Company adopted SFAS ASC 820-10-50, “Fair Value Measurements”. This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: · Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. · Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at December 31, 2016, the fair value of cash and cash equivalents was measured using Level 1 inputs. The Company’s financial instruments are cash and cash equivalents, restricted cash, VAT receivables, accounts payable and accrued liabilities and convertible debentures. The recorded values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments. k) Research and Development Costs In 2016, all research and development costs are charged to expense as incurred. The majority of these costs are in-house expenses related to consulting fees, materials, salaries of employees working on the R&D projects, rent and legal expenses related to patents. A breakdown of the R&D costs is as follows: Year Ended Year Ended December 31, December 31, 2016 2015 Research and Development Expenses $ $ Consulting fees 84,013 17,755 Legal fees 15,221 7,760 Office and Miscellaneous Expense 15,548 7,757 Payroll expense 739,500 459,498 R&D materials and supplies 132,207 617,613 Rent 29,082 8,820 Share-based compensation 312,187 486,591 Total 1,327,758 1,615,745 Savicell’s financing commitment related to the License and Research Funding Agreement (as defined in Note 4 below) entered into with Ramot at Tel Aviv University was completely fulfilled by December 31, 2015. l) Fixed Assets Equipment is recorded at cost and are amortized over their estimated useful life of 3 - 15 years on a straight-line basis. The amortization rates applicable to each category of property and equipment are as follows: Class of Properties Amortization Rate Furniture and Fixtures 15 -year; straight-line basis Computer Equipment 3 to 4 -year; straight-line basis Lab Equipment 3 to 15 -year; straight-line basis m) Convertible debentures Convertible debentures, for which the embedded conversion feature does not qualify for derivative treatment, is evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature as a debt discount, which is then accreted to interest expense over the life of the related debt using the effective interest method. n) Modifications to debt The Company evaluates any modifications to its debt in accordance with the applicable guidance in ASC 470-50, Debt-Modifications and Extinguishments. If the debt instruments are substantially modified, the modification is accounted for in the same manner as a debt extinguishment (i.e., a major modification) and the fees paid are recognized as expense at the time of the modification. Otherwise, such fees are deferred and amortized as an adjustment of interest expense over the remaining term of the modified debt instrument using the interest method. o) Recently Adopted Accounting Pronouncements In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The standard provides guidance that a performance target that affects vesting of a share-based payment and that could be achieved after the requisite service condition is a performance condition. As a result, the target is not reflected in the estimation of the award's grant date fair value. Share-based compensation cost for such award would be recognized over the required service period, if it is probable that the performance condition will be achieved. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The guidance should be applied on a prospective basis to awards that are granted or modified on or after the effective date of the standard. The Company adopted ASU 2014-09 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The ASU provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity's ability to continue as a going concern within one year of the date of issuance of the entity's financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is "substantial doubt about the entity's ability to continue as a going concern." The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter and early adoption is permitted. The Company has adopted the methodologies prescribed by this ASU by the date required and there is no material impact on the Company’s consolidated financial statements. In January 2015, the FASB issued ASU 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20), Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, which eliminates the concept of extraordinary items. Under this new guidance, entities will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendments in this update are effective for annual and interim periods beginning after December 15, 2015. The Company adopted ASU 2015-01 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis"("ASU 2015-02"). ASU 2015-02 makes several modifications to the consolidation guidance for variable interest entities ("VIEs") and general partners' investments in limited partnerships, as well as modifications to the evaluation of whether limited partnerships are VIEs or voting interest entities. It is effective for annual and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted ASU 2015-02 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations. In April 2015, FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). In August 2015, FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (“ASU 2015-15”). ASU 2015-03 will require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the debt. ASU 2015-15 allows an entity to present debt issuance costs associated with a revolving line of credit arrangement as an asset, regardless of whether a balance is outstanding. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03 or ASU 2015-15. These ASU’s are effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, with early adoption permitted. ASU 2015-03 requires the Company to reclassify its deferred financing costs associated with its long-term debt from other assets to long-term debt on a retrospective basis. The new standard does not affect the Company’s results of operations or cash flows. The Company adopted ASU 2015-15 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations. p) Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This accounting standard supersedes all existing US GAAP revenue recognition guidance. Under ASU 2014-09, a company will recognize revenue when it transfers the control of promised goods or services to customers in an amount that reflects the consideration which the company expects to collect in exchange for those goods or services. ASU 2014-09 will require additional disclosures in the notes to the consolidated financial statements and is effective for annual and interim reporting periods beginning after December 15, 2016. The Company is evaluating the impact of ASU 2014-09 and an estimate of the impact to the consolidated financial statements cannot be made at this time. On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. The ASU simplifies several aspects of the accounting for employee share-based payment transactions. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company has the adopted the methodologies prescribed by this ASU by the date required and there is no material impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after 15 December 2017, and interim periods within those years. For all other entities, it is effective for fiscal years beginning after 15 December 2018, and interim periods within fiscal years beginning after 15 December 2019. Early adoption is permitted. Entities will have to apply the guidance retrospectively, but if it is impracticable to do so for an issue, the amendments related to that issue would be applied prospectively. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements, if any. On November 17, 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. Entities will be required to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements, if any.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Text Block]	Note 3 – Property, Plant and Equipment As of December 31, 2016, the fixed assets balance on the financial statement consist of the following: Furniture and Computer Cost: Fixtures Equipment Lab Equipment Total December 31, 2015 $ 1,637 $ 19,117 $ 43,759 $ 64,513 Additions 1,859 7,372 673 9,904 December 31, 2016 $ 3,496 $ 26,489 $ 44,432 $ 74,417 Furniture and Computer Amortization: Fixtures Equipment Lab Equipment Total December 31, 2015 $ - $ 3,769 $ 2,423 $ 6,192 Additions 94 6,876 5,811 12,781 December 31, 2016 $ 94 $ 10,645 $ 8,234 $ 18,973 Furniture and Computer Net Book Value: Fixtures Equipment Lab Equipment Total December 31, 2015 $ 1,637 $ 15,348 $ 41,336 $ 58,321 December 31, 2016 $ 3,402 $ 15,844 $ 36,198 $ 55,444

License and Research Funding Ag

License and Research Funding Agreement	12 Months Ended
	Dec. 31, 2016
License and Research Funding Agreement [Text Block]	Note 4 – License and Research Funding Agreement On July 25, 2012, the Company’s subsidiary Savicell entered into a License and Research Funding Agreement (“R&D Agreement”) with Ramot at Tel Aviv University (“Ramot”) pursuant to which: • In the course of research performed at Tel-Aviv University (" TAU • Savicell wishes to fund further research at TAU relating to such technology; and • Savicell wishes to obtain a license from Ramot with respect to such technology and the results of such further funded research in order to develop and commercialize products in the diagnostics space, and Ramot wishes to grant the Company such license, all in accordance with the terms and conditions of this R&D Agreement. Pursuant to the above noted R&D Agreement, Savicell will fund research expenditures amounting to a total of $1,600,000 according to the following schedule: • $81,000 within 5 business days of the R&D Agreement (paid) • Before October 2012; $359,500 plus VAT as applicable (paid) • Before January 3, 2013; $359,500 plus VAT as applicable (paid) • Before April 3, 2013; $400,000 plus VAT as applicable (paid) • Before July 3, 2013; $400,000 plus VAT as applicable (paid) The payments originally due on April 3, 2013 and July 3, 2013 were postponed by the parties until such time as the funds were actually required in furtherance of the joint research and development initiatives. As of December 31, 2015, Savicell’s entire financing commitment has been met and no more expenditures are mandated by the R&D Agreement on behalf of Ramot. Savicell is continuing the clinical research within its own laboratory situated in Haifa, Israel. In addition, Savicell agreed to issue to Ramot warrants (the “Warrants”) to purchase a number of ordinary shares of Savicell which shall together comprise 15% of issued shares of Savicell on an as-converted, fully diluted basis (equivalent to 1,765 Warrant Shares of Savicell). The Warrants shall be exercisable at an exercise price equal to the par value of the Warrant Shares, at any time and from time to time before Savicell completes a deemed liquidity event or the first underwritten offering of the Savicell's ordinary shares to the general public. The fair value of the Warrant Shares has been estimated at $1,698.97 per Warrant Share which is equivalent to the price at which Savicell has issued shares to third parties, for a total of $2,998,682 which has been included in research and development costs. As the exercise price inherent in the warrant certificate to purchase 1,765 common shares of Savicell is at nominal value, the warrant certificate is valued at the price of the subsequent equity issuance by Savicell ($1,698.97 per share) and the related common shares are considered to be issued and outstanding. Upon successful development and commercialization of the technology, and in recognition of the rights and licenses granted to Savicell pursuant to this R&D Agreement, Savicell will be subject to (a) royalties based on the worldwide sales related to the technology; and (b) minimum annual royalties with respect to any calendar year following the first commercial sales as follows. The minimum annual royalties are subject to increases for each successive year. During the year ended December 31, 2016, Savicell incurred research and development costs of $1,327,758 (2015 -$1,615,745) which were included in the consolidated statements of operations and comprehensive loss.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Text Block]	Note 5 – Related Party Transactions The Company completed the following related party transactions: During the year ended December 31, 2016, the Company incurred consulting fees and salaries of $581,943 (December 31, 2015 - $538,072) payable to its directors and officers. The Company incurred consulting fees payable to a company controlled by a former director/officer of $108,000 (December 31, 2015 - $108,000). As at December 31, 2016, included in accounts payable and accrued liabilities are amounts of $6,300 (December 31, 2015 - nil) that was payable to a company controlled by a former director/officer of the Company and $34,609 (December 31, 2015-$16,325) that was payable to current officers or directors of the Company. As at December 31, 2016, the Company settled debts to its directors and officers in the aggregate amount of $172,895 with an unsecured and non-interest bearing convertible debenture (Note 6). On November 4, 2011, the Company entered into a loan Agreement (“Loan Agreement”) with a shareholder of the Company to settle a loan payable in the amount of $74,062. Pursuant to the Loan Agreement, the terms of repayment were amended to specify that ten per cent ( 10%) of the gross proceeds of any prospective debt or equity financing undertaken by ODT would be applied to the repayment of the principal of this loan until fully repaid. The term loan was unsecured, non-interest bearing and required that any balance remaining outstanding on November 4, 2016 would then be fully due and payable. On May 28, 2015, the Company entered into a debt settlement agreement pursuant to which the Company settled the term loan in the aggregate amount of $74,062 by the issuance of 462,890 common shares at a per share price of $0.16. The Company recognized a loss on extinguishment of $36,987 to additional paid in capital.

Convertible debentures

Convertible debentures	12 Months Ended
	Dec. 31, 2016
Convertible debentures [Text Block]	Note 6 – Convertible debentures On April 15, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $852,418. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.055 over a seven year term. On December 31, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $188,085 with an unsecured and non-interest bearing convertible debenture. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a seven year term. On December 31, 2016, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $172,895 with an unsecured and non-interest bearing convertible debenture. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a seven-year term. The Company evaluated these convertible debentures for derivatives and determined that they do not qualify for derivative treatment. The Company then evaluated the debenture for beneficial conversion features and determined that the convertible loan issued on April 15, 2015 does contain beneficial conversion features. The aggregate intrinsic value of the beneficial conversion features was determined to be $852,418. This amount was recorded as a debt discount on April 15, 2015 that is being amortized over the life of the debenture at effective interest rate of 77%. Total debt discount amortization during the year ended December 31, 2016 was $368,496. (December 31, 2015 – $192,114) December 31, 2015 Additions December 31, 2016 Convertible debentures $ 1,040,503 $ 172,894 $ 1,213,397 Convertible discount (852,418 ) - (852,418 ) Net convertible debentures 188,085 172,894 360,979 Interest accretion 192,114 176,382 368,496 Balance $ 380,199 $ 349,276 $ 729,475

Equity

Equity	12 Months Ended
	Dec. 31, 2016
Equity [Text Block]	Note 7 –Equity Common shares The Company has authorized 500,000,000 common shares at par value of $0.001 per share. On April 19, 2015, the Company issued 3,550,000 common shares at $0.20 per share for total proceeds of $710,000. On May 22, 2015, the Company issued 500,000 common shares at $0.20 per share for total proceeds of $100,000. On May 28, 2015, the Company entered into a debt settlement agreement pursuant to which the Company settled a related party term loan in the aggregate amount of $74,062 by the issuance of 462,890 common shares at $0.20 per share. On June 23 2015, stock options previously granted by the Company were exercised resulting in the issuance of 481,179 common shares at $0.01 per share for total proceeds of $4,812. On June 23, 2015, stock options previously granted by the Company were exercised resulting in the issuance of 100,000 common shares at $0.01 per share for total proceeds of $1,000. On June 25, 2015, the Company issued 5,000,000 common shares at $0.20 per share for total proceeds of $1,000,000. On July 20, 2015, four shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 3,824,922 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $611,987. On September 3, 2015, three shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,786,250 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $285,800. On October 20, 2015, two shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 637,500 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $102,000. As at January 31, 2016, three shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,756,619 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $281,059. On March 31, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 2,198,819 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $351,811. On March 31, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 318,742 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $50,999. On April 18, 2016, the Company issued 625,000 common shares at $0.20 per share for total proceeds of $125,000. On April 21, 2016, two shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 824,992 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $131,999. On April 22, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 318,749 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $50,999. On June 6, 2016, eight shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,115,625 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $178,500. On June 14, 2016, the Company issued 2,500,000 common shares at $0.20 per share for total proceeds of $500,000. On July 5, 2016, stock options previously granted by the Company were exercised resulting in the issuance of 50,000 common shares at $0.01 per share for total proceeds of $500. On July 7, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 839,375 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $134,300. On September 1, 2016, eight shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 4,653,732 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $744,597. For the year ended December 31, 2016, the Company recorded share issue cost of $nil (December 31, 2015 - $15,000) for the shares issued. In December 2016, the Company received $158,750 toward the subscription for 793,750 common shares. The shares have not yet been issued subsequent to the year-end. As at December 31, 2016, the Company has 114,180,828 common shares issued and outstanding. Preferred Shares The Company has authorized 20,000,000 preferred shares at a par value of $0.001 per share. No preferred shares have been issued by the Company and accordingly none are outstanding. Stock Options On May 28, 2013, the Company granted a total of 962,358 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for five years. A quarter of the options will vest on each of the first four anniversaries of the date of initial grant. The options were valued based on the Black Scholes model. On June 22, 2015, 481,179 of these options were exercised at $0.01 per share for total proceeds of $4,812. For the year ended December 31, 2016, the Company recorded stock based compensation of $17,628 (2015: $112,888) for such options. On August 22, 2013, the Company granted a total of 800,000 stock options to a consultant. The stock options are exercisable at the exercise price of $0.01 per share and may be exercised for five years. 480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years from August 22, 2013. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant to the Company. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $28,419 (2015: $72,453) for such options. On November 11, 2013, the Company granted a total of 1,924,717 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for seven years. A quarter of the options will vest immediately and a quarter on each of the first three anniversaries of the date of initial grant. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $26,364 (2015: $154,271) for such options. On January 1, 2014, the Company granted a total of 500,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for five years. A quarter of the options will vest immediately and a quarter will vest at end of each completed year that the consultant provides the services. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $10,585 (2015: $52,865) for such options. On May 4, 2014 the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for seven years. One third of the options will vest at end of each completed year that the consultant provides the services. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $208 (2015: $982) for such options. On May 15, 2014 the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for five years. 25,000 of the options will vest immediately. Furthermore, 75,000 and 50,000 of the options respectively will vest on the first and second anniversaries that the consultant provides the services. The options were valued based on the Black Scholes model. For the year ended December 31 2016, the Company recorded stock based compensation of ($12) (2015: $24,016) for such options. In addition, on June 23, 2015, 100,000 of these options were exercised at $0.01 per share for total proceeds of $1,000. On August 4, 2015 the Company granted a total of 150,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for six years. One third of the options will vest at end of each of June 21, 2016, June 21, 2017 and June 21, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the year ended December 31 2016, the Company recorded stock based compensation of $9,347 (2015: $5,413) for such options. In August 2015 the Company granted a total of 1,730,000 stock options to four advisors of the Company. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for six-seven years. One third of the options will vest at end of each completed year for which the consultant provides the services. The options were valued based on the Black Scholes model. For year ended December 31, 2016, the Company recorded stock based compensation of $107,843 (2015: $53,701) for such options. On September 1, 2015 the Company granted a total of 150,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of September 1, 2015, September 1, 2016 and September 1, 2017 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For year ended December 31, 2016, the Company recorded stock based compensation of $12,098 (2015: $4,879) for such options. On November 22, 2015 the Company granted a total of 50,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of November 22, 2016, November 22, 2017 and November 22, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For year ended December 31, 2016, the Company recorded stock based compensation of $4,482 (2015: $500) for such options. On December 1, 2015 the Company granted a total of 125,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of December 1, 2016, December 1, 2017 and December 1, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For year ended December 31, 2016, the Company recorded stock based compensation of $11,393 (2015: $978) for such options. On December 6, 2015 the Company granted a total of 100,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of December 6, 2016, December 6, 2017 and December 6, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For year ended December 31, 2016, the Company recorded stock based compensation of $9,436 (2015: 677) for such options. On February 15, 2016 the Company granted a total of 50,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $2,894 for such options. On March 7, 2016 the Company granted a total of 75,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For year ended December 31, 2016, the Company recorded stock based compensation of $4,425 for such options. On May 5, 2016 the Company granted a total of 150,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for ten years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $13,385 for such options. On June 6, 2016 the Company granted a total of 800,000 stock options to a consultant. The stock options are exercisable at the exercise price of $0.20 per share and may be exercised for five years. 480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years following June 6, 2016. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant to the Company. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $23,746 for such options. On November 1, 2016, the Company granted a total of 360,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One half of the options will vest immediately and one-half shall vest on the on the first anniversary date of grant provided the grantee remains a board member of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the year ended December 31, 2016, the Company recorded stock based compensation of $29,946 for such options. The fair value of each option grant is calculated using the following assumptions: 2016 2015 Expected life – year 3 - 10 3 - 7 Interest rate 0.73 – 2.45% 0.97 – 2.09% Volatility 65.99 – 99.04% 62.86 – 94.97% Dividend yield - -% - -% Forfeiture rate - -% - -% Number of Options Weighted Expire date Average Exercise Price Balance, December 31, 2014 14,237,075 $ 0.01 Exercised, on June 23, 2015 (481,179 ) 0.01 Exercised, on June 25, 2015 (100,000 ) 0.01 Granted, on August 4, 2015 150,000 0.20 May 4, 2022 Granted, on August 7, 2015 1,610,000 0.20 August 7, 2022 Granted, on August 25, 2015 120,000 0.20 August 25, 2022 Granted, on September 1, 2015 150,000 0.20 September 1, 2022 Granted, on November 22, 2015 50,000 0.20 November 22, 2022 Granted, on December 1, 2015 125,000 0.20 December 1, 2022 Granted, on December 6, 2015 100,000 0.20 December 6, 2022 Balance, December 31, 2015 15,960,896 $ 0.04 Granted, on February 15, 2016 50,000 0.20 February 15, 2023 Granted, on March 7, 2016 75,000 0.20 March 7, 2023 Granted, on May 5, 2016 150,000 0.20 May 5, 2026 Granted, on June 6, 2016 800,000 0.20 June 6, 2021 Exercised, on July 7, 2016 (50,000 ) 0.01 Granted, on November 1, 2016 360,000 0.20 October 31, 2023 Balance, December 31, 2016 17,345,896 $ 0.05 Outstanding as at December 31, 2016 Exercisable as at December 31, 2016 Weighted Weighted Weighted Average Weighted Average Exercise Average Remaining Average Remaining Price Number of Exercise Contractual Number of Exercise Contractual Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.67 9,750,000 $ 0.01 5.67 0.01 481,179 0.01 1.41 240,589 0.01 1.41 0.01 800,000 0.01 1.64 680,001 0.01 1.64 0.01 1,924,717 0.01 3.87 1,924,717 0.01 3.87 0.01 500,000 0.01 2.00 500,000 0.01 2.00 0.01 150,000 0.01 4.34 100,000 0.01 4.34 0.20 150,000 0.20 4.34 50,000 0.20 4.34 0.20 120,000 0.20 5.65 40,000 0.20 5.65 0.20 1,610,000 0.20 5.60 536,667 0.20 5.60 0.20 150,000 0.20 5.67 100,000 0.20 5.67 0.20 50,000 0.20 5.90 16,667 0.20 5.90 0.20 125,000 0.20 5.92 41,667 0.20 5.92 0.20 100,000 0.20 5.93 33,333 0.20 5.93 0.20 50,000 0.20 6.13 - - - 0.20 75,000 0.20 6.18 - - - 0.20 150,000 0.20 9.35 30,000 0.20 9.35 0.20 800,000 0.20 4.43 26,667 0.20 4.43 0.20 360,000 0.20 6.84 180,000 0.20 6.84 17,345,896 $ 0.05 5.03 14,250,308 $ 0.02 5.04 Outstanding as at December 31, 2015 Exercisable as at December 31, 2015 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 6.67 9,750,000 $ 0.01 6.67 0.01 481,179 0.01 2.41 - - - 0.01 800,000 0.01 2.64 453,334 0.01 2.64 0.01 1,924,717 0.01 4.87 1,443,538 0.01 4.87 0.01 500,000 0.01 3.01 333,334 0.01 3.01 0.01 150,000 0.01 5.35 50,000 0.01 5.35 0.01 50,000 0.01 3.37 - - - 0.20 150,000 0.20 5.35 - - - 0.20 120,000 0.20 6.65 - - - 0.20 1,610,000 0.20 6.61 - - - 0.20 150,000 0.20 6.67 50,000 0.20 6.67 0.20 50,000 0.20 6.90 - - - 0.20 125,000 0.20 6.92 - - - 0.20 100,000 0.20 6.94 - - - 15,960,896 $ 0.04 5.97 12,080,205 $ 0.01 6.20 Non-Controlling Interests The Company’s subsidiary, Savicell, granted a third party a warrant certificate to purchase 1,765 common shares of Savicell that initially represented 15% of the underlying common equity of Savicell. In the course of its initial equity issuances up to October 30, 2012 (the “Initial Closing”), Savicell issued a total of 592 ordinary shares at $1,698.97 per share to the non-related third party representing approximately 4.79% of the fully diluted common equity of Savicell for aggregate proceeds of $1,005,795. The Savicell investors are entitled to convert their Savicell shares into common shares of ODT at a price equal to 80% of the per share pricing of the first completed ODT financing of over $500,000 conducted after July 1, 2012 (the “Financing Price”) provided that for purposes of such conversion, the deemed maximum Financing Price shall be the per share price of the common shares of ODT based on (a) an aggregate ODT equity valuation of $30,000,000 ; and (b) the number of common shares of ODT outstanding at the time of the financing. Savicell continued its equity issuances following the Initial Closing. As at December 31, 2012, Savicell had issued a total of 684 shares at $1,698.97 per share representing approximately 5.11% of the fully diluted common equity of Savicell for aggregate proceeds of $1,162,192. During the year ended December 31, 2013, Savicell issued a total of 760 shares at $1,700 per share representing approximately 5.68% of the fully diluted common equity of Savicell for aggregate proceeds of $1,292,000. During the year ended December 31, 2014, Savicell issued a total of 183 shares at $1,699 per share representing approximately 1.37% of the fully diluted common equity of Savicell for aggregate proceeds of $310,977. During the year ended December 31, 2015, Savicell issued a total of 417 shares at $1,700 per share to third parties for aggregate proceeds of $709,087. As at December 31, 2015, Savicell also issued 516 shares at $1,700 to ODT, which of $532,084 has not been received as at December 31, 2015. In addition, Savicell investors exchanged 588 Savicell shares for 6,248,672 of ODT common shares with ODT receiving the Savicell shares so exchanged. Following these share issuances, the Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 77.00%, 12.6% and 10.4% respectively (December 31, 2014-74.67%, 13.18% and 12.15%) . During the year ended December 31, 2016, Savicell investors exchanged 1,132 Savicell shares for 12,026,654 of ODT common shares with ODT receiving the Savicell shares so exchanged. As at December 31, 2016, Savicell received $1,786,656 from ODT and issued 1,051 shares to ODT in return. Following these share issuances, the Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 86.13%, 11.72% and 2.15%, respectively (December 31, 2015-77%, 12.6% and 10.4%) . As a result, ODT’s shareholding increased, which decreased the additional paid-in capital by 2,152,695 during the year. Savicell’s Common Shares Number Amount of Shares Balance, December 31, 2013 13,209 $ 2,454,192 Issued for cash pursuant to share subscriptions 183 310,977 Balance, December 31, 2014 13,392 2,765,169 Issued for cash pursuant to share subscriptions 730 1,241,171 Shares issued to settle inter-company debts 203 345,198 Share subscription receivable (313 ) (532,084 ) Balance, December 31, 2015 14,012 3,819,454 Shares issued to settle inter-company debts 1,051 1,786,656 Balance, December 31, 2016 15,063 $ 5,606,110 As the exercise price inherent in the warrant certificate to purchase 1,765 common shares of Savicell is at nominal value, the warrant certificate is valued at the price of the subsequent equity issuance by Savicell ($1,698.97 per share) and the related common shares are considered to be issued and outstanding.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Taxes [Text Block]	Note 8 – Income Taxes The Company and Savicell are subject to income tax laws in their respective tax jurisdictions, which are the same as their respective place of incorporation. The following table reconciles the income tax benefit at the U.S. Federal statutory rate to income tax benefit at the Company's effective tax rates. For the year ended For the year ended December 31, 2016 December 31, 2015 $ $ Net loss before taxes (2,232,021 ) (2,589,234 ) Statutory tax rate 34% 34% Income tax recovery (758,887 ) (880,340 ) Non-deductible item 77,623 131,208 Change in estimates - (515,645 ) Change enacted tax rate - 20,367 Foreign tax rate difference 122,231 142,616 Discount on convertible debenture - 289,824 Change in valuation allowance 559,033 811,970 Income tax expense (recovery) - - Deferred taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. Deferred tax assets (liabilities) at December 31, 2016 and 2015 are comprised of the following: December 31, 2016 December 31, 2015 $ $ Loss carry forwards 3,811,063 3,312,236 Convertible debenture (148,971 ) (209,177 ) Valuation allowance (3,662,092 ) (3,103,059 ) Deferred tax assets - - As at December 31, 2016, the Company's US net operating loss carry forwards total $7,912,409 (2015 - $7,356,417),subject to the final determination by taxation authorities. These losses expire as follow: Year Total 2029 $ 3,163 2030 69,495 2031 98,143 2032 4,426,198 2033 1,019,303 2034 1,186,199 2035 553,916 2036 555,992 $ 7,912,409 As at December 31, 2016, the Company's Israeli net operating loss carry forwards total $4,483,377 (2015 – $3,244,221), subject to the final determination by taxation authorities. These losses carry forward indefinitely. The deferred tax assets have not been recognized because at this stage of the Company’s development, it is not determinable that future taxable profit will be available against which the Company can utilize such deferred tax assets.

Commitments And Guarantees

Commitments And Guarantees	12 Months Ended
	Dec. 31, 2016
Commitments And Guarantees [Text Block]	Note 9 – Commitments and Guarantees The Company did not become a guarantor to any parties as at December 31, 2016. 1. On September 11, 2012, ODT signed an employment agreement with Giora Davidovits, its chief executive officer and President, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief executive officer, the Company will provide Mr. Davidovits an annual salary of $250,000 together with other benefits and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Giora Davidovits options to purchase 3,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 2. On October 30, 2012, ODT and Savicell signed an employment agreement with Eyal Davidovits, its chief operating officer, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief operating officer, the Company will provide Mr. Davidovits an annual salary of $112,324 (NIS 432,000), together with other fringe benefits including those related to the use of an automobile, health insurance, contributions to government run retirement programs and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Eyal Davidovits options to purchase 2,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 3. On November 8, 2012, ODT and Savicell signed an employment agreement with Dr. Irit Arbel, its vice president, research and development, which agreement entailed an effective date of September 1, 2012. In return for acting as its new vice president, research and development officer, the Company will provide Dr. Arbel an annual salary of $106,084 (NIS 408,000) together with other fringe benefits, health insurance, contributions to government run retirement programs and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Irit Arbel options to purchase 2,000,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Dr. Arbel is eligible for subsequent option grants at the discretion of the board of directors. 4. On July 20, 2015, the Company signed an operating lease agreement to lease offices for a period ending July 31, 2018 with an option to renew the lease for an additional period of 2 years. The monthly lease expense is $3,152 (NIS 12,121). Future minimum lease commitment under the operating lease agreement is approximately $59,888 (NIS 339,388). The Company pledged a bank deposit which is used as a bank guarantee at an amount of $13,254 (NIS 50,000) to secure its payments under the lease agreement. The minimum future payments for the above commitments are as follows: Consulting fee and Year Salaries Office rent Total 2017 $ 312,272 $ 37,824 $ 350,096 2018 - 22,064 22,064 Total $ 312,272 $ 59,888 $ 372,160

Geographic Information

Geographic Information	12 Months Ended
	Dec. 31, 2016
Geographic Information [Text Block]	Note 10 – Geographic Information The Company’s head office is located in the United States (“US”). The operations of the Company are primarily in two geographic areas: the US and Israel. A summary of geographical information for the Company’s long lived assets is as follows: Year ended December 31, 2016 US Israel Total Long-live assets $ - $ 55,444 $ 55,444 Year ended December 31, 2015 US Israel Total Long-live assets $ - $ 58,321 $ 58,321

Supplemental Disclosure with Re

Supplemental Disclosure with Respect to Cash Flows	12 Months Ended
	Dec. 31, 2016
Supplemental Disclosure with Respect to Cash Flows [Text Block]	Note 11 – Supplemental Disclosure with Respect to Cash Flows December 31, 2016 December 31, 2015 $ $ Convertible debentures issued for debt 172,894 1,040,503

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Text Block]	Note 12 – Subsequent Events 1. On February 22, 2017, the Company received $30,000 toward the subscription for 150,000 common shares of the Company. 2. On March 20, 2017, the Company received $50,000 toward the subscription for 250,000 common shares of the Company.

Comparative Information

Comparative Information	12 Months Ended
	Dec. 31, 2016
Comparative Information [Text Block]	Note 13 – Comparative Information Comparative figures related to the R&D expenses have been reclassified to conform to the current year’s presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Basis of Presentation [Policy Text Block]	a) Basis of Presentation These consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) and are expressed in United States dollars, unless otherwise noted. All adjustments considered necessary for a fair presentation of financial position, results of operations and cash flows as at December 31, 2016 have been included.
Principles of Consolidation [Policy Text Block]	b) Principles of Consolidation These consolidated financial statements include the accounts of the Company and its 86.13% (December 31, 2015-77.00%) interest in Savicell. All significant intercompany accounts and transactions have been eliminated upon consolidation.
Use of Estimates [Policy Text Block]	c) Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred income tax assets and determination of useful lives of property, plant and equipment.
Foreign Currency Translation [Policy Text Block]	d) Foreign Currency Translation The Company’s functional currency is the U.S. dollar. Transactions in other currencies are recorded in U.S. dollars at the rates of exchange prevailing when the transactions occur. Monetary assets and liabilities denominated in other currencies are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates. Exchange gains and losses are recorded in the statements of operations. The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). All transactions are recorded in NIS. Monetary assets and liabilities denominated in NIS are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates and expenses are translated at the average exchange rates. Gains and losses from such translations are included in stockholders’ equity, as a component of other comprehensive income. In the year ended 2013, Savicell’s functional currency was the U.S. dollar. During the year 2014, with the increased volume of transactions in the local currency, the management reassessed Savicell’s functional currency to NIS based on the change in facts and effective as of January 1, 2014. Such change is still appropriate in 2016. As a result of the functional currency change discussed above, a cumulative translation adjustment of $540 is included in accumulated other comprehensive income and will only be adjusted in the event of a full or partial disposition of the Company's investment in Savicell.
Cash and Cash Equivalents [Policy Text Block]	e) Cash and Cash Equivalents Cash and cash equivalents consist entirely of readily available cash balances. There were no cash equivalents as of December 31, 2016 and 2015.
Stock-based Compensation [Policy Text Block]	f) Stock-based Compensation The Company accounts for its stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, including grants of employee stock options, to be recognized as expense in the statements of operations based on their grant date fair values. For stock options granted to employees and to members of the Board of Directors for their services on the Board of Directors, the Company estimates the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. Share-based payments issued to non-employees are recorded at their fair values at each reporting date, as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on a straight-line basis.
Income Taxes [Policy Text Block]	g) Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, deferred tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply when the asset is realized or the liability is settled. The effect of a change in income tax rates on deferred tax liabilities and assets is recognized in income in the period in which the change occurs. Deferred tax assets are recognized to the extent that they are considered more likely than not to be realized. Per FASB ASC 740 “Income taxes” under the liability method, it is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At December 31, 2016, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company’s tax positions are recorded as Interest Expense.
Comprehensive Income (Loss) [Policy Text Block]	h) Comprehensive Income (Loss) The Company accounts for comprehensive income under the provisions of ASC Topic 220-10, Comprehensive Income - Overall, which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing this information on its Statements of Operations and Comprehensive Loss.
Earnings (Loss) Per Share [Policy Text Block]	i) Earnings (Loss) Per Share Basic loss per share is computed on the basis of the weighted average number of common shares outstanding during each period. Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the year ended December 31, 2016 and 2015 because the inclusion of such underlying shares would have had an anti-dilutive effect.
Financial Instruments and Fair Value of Financial Instruments [Policy Text Block]	j) Financial Instruments and Fair Value of Financial Instruments Fair Value of Financial Instruments – the Company adopted SFAS ASC 820-10-50, “Fair Value Measurements”. This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: · Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. · Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at December 31, 2016, the fair value of cash and cash equivalents was measured using Level 1 inputs. The Company’s financial instruments are cash and cash equivalents, restricted cash, VAT receivables, accounts payable and accrued liabilities and convertible debentures. The recorded values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments.
Research and Development Costs [Policy Text Block]	k) Research and Development Costs In 2016, all research and development costs are charged to expense as incurred. The majority of these costs are in-house expenses related to consulting fees, materials, salaries of employees working on the R&D projects, rent and legal expenses related to patents. A breakdown of the R&D costs is as follows: Year Ended Year Ended December 31, December 31, 2016 2015 Research and Development Expenses $ $ Consulting fees 84,013 17,755 Legal fees 15,221 7,760 Office and Miscellaneous Expense 15,548 7,757 Payroll expense 739,500 459,498 R&D materials and supplies 132,207 617,613 Rent 29,082 8,820 Share-based compensation 312,187 486,591 Total 1,327,758 1,615,745 Savicell’s financing commitment related to the License and Research Funding Agreement (as defined in Note 4 below) entered into with Ramot at Tel Aviv University was completely fulfilled by December 31, 2015.
Fixed Assets [Policy Text Block]	l) Fixed Assets Equipment is recorded at cost and are amortized over their estimated useful life of 3 - 15 years on a straight-line basis. The amortization rates applicable to each category of property and equipment are as follows: Class of Properties Amortization Rate Furniture and Fixtures 15 -year; straight-line basis Computer Equipment 3 to 4 -year; straight-line basis Lab Equipment 3 to 15 -year; straight-line basis
Convertible debentures [Policy Text Block]	m) Convertible debentures Convertible debentures, for which the embedded conversion feature does not qualify for derivative treatment, is evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature as a debt discount, which is then accreted to interest expense over the life of the related debt using the effective interest method.
Modifications to debt [Policy Text Block]	n) Modifications to debt The Company evaluates any modifications to its debt in accordance with the applicable guidance in ASC 470-50, Debt-Modifications and Extinguishments. If the debt instruments are substantially modified, the modification is accounted for in the same manner as a debt extinguishment (i.e., a major modification) and the fees paid are recognized as expense at the time of the modification. Otherwise, such fees are deferred and amortized as an adjustment of interest expense over the remaining term of the modified debt instrument using the interest method.
Recently Adopted Accounting Pronouncements [Policy Text Block]	o) Recently Adopted Accounting Pronouncements In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. The standard provides guidance that a performance target that affects vesting of a share-based payment and that could be achieved after the requisite service condition is a performance condition. As a result, the target is not reflected in the estimation of the award's grant date fair value. Share-based compensation cost for such award would be recognized over the required service period, if it is probable that the performance condition will be achieved. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The guidance should be applied on a prospective basis to awards that are granted or modified on or after the effective date of the standard. The Company adopted ASU 2014-09 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The ASU provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity's ability to continue as a going concern within one year of the date of issuance of the entity's financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is "substantial doubt about the entity's ability to continue as a going concern." The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter and early adoption is permitted. The Company has adopted the methodologies prescribed by this ASU by the date required and there is no material impact on the Company’s consolidated financial statements. In January 2015, the FASB issued ASU 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20), Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, which eliminates the concept of extraordinary items. Under this new guidance, entities will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendments in this update are effective for annual and interim periods beginning after December 15, 2015. The Company adopted ASU 2015-01 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis"("ASU 2015-02"). ASU 2015-02 makes several modifications to the consolidation guidance for variable interest entities ("VIEs") and general partners' investments in limited partnerships, as well as modifications to the evaluation of whether limited partnerships are VIEs or voting interest entities. It is effective for annual and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted ASU 2015-02 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations. In April 2015, FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). In August 2015, FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (“ASU 2015-15”). ASU 2015-03 will require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the debt. ASU 2015-15 allows an entity to present debt issuance costs associated with a revolving line of credit arrangement as an asset, regardless of whether a balance is outstanding. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03 or ASU 2015-15. These ASU’s are effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, with early adoption permitted. ASU 2015-03 requires the Company to reclassify its deferred financing costs associated with its long-term debt from other assets to long-term debt on a retrospective basis. The new standard does not affect the Company’s results of operations or cash flows. The Company adopted ASU 2015-15 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's consolidated financial position or results of operations.
Recently Issued Accounting Pronouncements [Policy Text Block]	p) Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This accounting standard supersedes all existing US GAAP revenue recognition guidance. Under ASU 2014-09, a company will recognize revenue when it transfers the control of promised goods or services to customers in an amount that reflects the consideration which the company expects to collect in exchange for those goods or services. ASU 2014-09 will require additional disclosures in the notes to the consolidated financial statements and is effective for annual and interim reporting periods beginning after December 15, 2016. The Company is evaluating the impact of ASU 2014-09 and an estimate of the impact to the consolidated financial statements cannot be made at this time. On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. The ASU simplifies several aspects of the accounting for employee share-based payment transactions. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company has the adopted the methodologies prescribed by this ASU by the date required and there is no material impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after 15 December 2017, and interim periods within those years. For all other entities, it is effective for fiscal years beginning after 15 December 2018, and interim periods within fiscal years beginning after 15 December 2019. Early adoption is permitted. Entities will have to apply the guidance retrospectively, but if it is impracticable to do so for an issue, the amendments related to that issue would be applied prospectively. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements, if any. On November 17, 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. Entities will be required to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements, if any.

Significant Accounting Polici21

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Research and Development Costs [Table Text Block]	Year Ended Year Ended December 31, December 31, 2016 2015 Research and Development Expenses $ $ Consulting fees 84,013 17,755 Legal fees 15,221 7,760 Office and Miscellaneous Expense 15,548 7,757 Payroll expense 739,500 459,498 R&D materials and supplies 132,207 617,613 Rent 29,082 8,820 Share-based compensation 312,187 486,591 Total 1,327,758 1,615,745
Schedule of Properties Estimated Useful life [Table Text Block]	Class of Properties Amortization Rate Furniture and Fixtures 15 -year; straight-line basis Computer Equipment 3 to 4 -year; straight-line basis Lab Equipment 3 to 15 -year; straight-line basis

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Property, Plant and Equipment [Table Text Block]	Furniture and Computer Cost: Fixtures Equipment Lab Equipment Total December 31, 2015 $ 1,637 $ 19,117 $ 43,759 $ 64,513 Additions 1,859 7,372 673 9,904 December 31, 2016 $ 3,496 $ 26,489 $ 44,432 $ 74,417 Furniture and Computer Amortization: Fixtures Equipment Lab Equipment Total December 31, 2015 $ - $ 3,769 $ 2,423 $ 6,192 Additions 94 6,876 5,811 12,781 December 31, 2016 $ 94 $ 10,645 $ 8,234 $ 18,973 Furniture and Computer Net Book Value: Fixtures Equipment Lab Equipment Total December 31, 2015 $ 1,637 $ 15,348 $ 41,336 $ 58,321 December 31, 2016 $ 3,402 $ 15,844 $ 36,198 $ 55,444

Convertible debentures (Tables)

Convertible debentures (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Convertible Debt [Table Text Block]	December 31, 2015 Additions December 31, 2016 Convertible debentures $ 1,040,503 $ 172,894 $ 1,213,397 Convertible discount (852,418 ) - (852,418 ) Net convertible debentures 188,085 172,894 360,979 Interest accretion 192,114 176,382 368,496 Balance $ 380,199 $ 349,276 $ 729,475

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 Expected life – year 3 - 10 3 - 7 Interest rate 0.73 – 2.45% 0.97 – 2.09% Volatility 65.99 – 99.04% 62.86 – 94.97% Dividend yield - -% - -% Forfeiture rate - -% - -%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Options Weighted Expire date Average Exercise Price Balance, December 31, 2014 14,237,075 $ 0.01 Exercised, on June 23, 2015 (481,179 ) 0.01 Exercised, on June 25, 2015 (100,000 ) 0.01 Granted, on August 4, 2015 150,000 0.20 May 4, 2022 Granted, on August 7, 2015 1,610,000 0.20 August 7, 2022 Granted, on August 25, 2015 120,000 0.20 August 25, 2022 Granted, on September 1, 2015 150,000 0.20 September 1, 2022 Granted, on November 22, 2015 50,000 0.20 November 22, 2022 Granted, on December 1, 2015 125,000 0.20 December 1, 2022 Granted, on December 6, 2015 100,000 0.20 December 6, 2022 Balance, December 31, 2015 15,960,896 $ 0.04 Granted, on February 15, 2016 50,000 0.20 February 15, 2023 Granted, on March 7, 2016 75,000 0.20 March 7, 2023 Granted, on May 5, 2016 150,000 0.20 May 5, 2026 Granted, on June 6, 2016 800,000 0.20 June 6, 2021 Exercised, on July 7, 2016 (50,000 ) 0.01 Granted, on November 1, 2016 360,000 0.20 October 31, 2023 Balance, December 31, 2016 17,345,896 $ 0.05
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Outstanding as at December 31, 2016 Exercisable as at December 31, 2016 Weighted Weighted Weighted Average Weighted Average Exercise Average Remaining Average Remaining Price Number of Exercise Contractual Number of Exercise Contractual Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.67 9,750,000 $ 0.01 5.67 0.01 481,179 0.01 1.41 240,589 0.01 1.41 0.01 800,000 0.01 1.64 680,001 0.01 1.64 0.01 1,924,717 0.01 3.87 1,924,717 0.01 3.87 0.01 500,000 0.01 2.00 500,000 0.01 2.00 0.01 150,000 0.01 4.34 100,000 0.01 4.34 0.20 150,000 0.20 4.34 50,000 0.20 4.34 0.20 120,000 0.20 5.65 40,000 0.20 5.65 0.20 1,610,000 0.20 5.60 536,667 0.20 5.60 0.20 150,000 0.20 5.67 100,000 0.20 5.67 0.20 50,000 0.20 5.90 16,667 0.20 5.90 0.20 125,000 0.20 5.92 41,667 0.20 5.92 0.20 100,000 0.20 5.93 33,333 0.20 5.93 0.20 50,000 0.20 6.13 - - - 0.20 75,000 0.20 6.18 - - - 0.20 150,000 0.20 9.35 30,000 0.20 9.35 0.20 800,000 0.20 4.43 26,667 0.20 4.43 0.20 360,000 0.20 6.84 180,000 0.20 6.84 17,345,896 $ 0.05 5.03 14,250,308 $ 0.02 5.04	Outstanding as at December 31, 2015 Exercisable as at December 31, 2015 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 6.67 9,750,000 $ 0.01 6.67 0.01 481,179 0.01 2.41 - - - 0.01 800,000 0.01 2.64 453,334 0.01 2.64 0.01 1,924,717 0.01 4.87 1,443,538 0.01 4.87 0.01 500,000 0.01 3.01 333,334 0.01 3.01 0.01 150,000 0.01 5.35 50,000 0.01 5.35 0.01 50,000 0.01 3.37 - - - 0.20 150,000 0.20 5.35 - - - 0.20 120,000 0.20 6.65 - - - 0.20 1,610,000 0.20 6.61 - - - 0.20 150,000 0.20 6.67 50,000 0.20 6.67 0.20 50,000 0.20 6.90 - - - 0.20 125,000 0.20 6.92 - - - 0.20 100,000 0.20 6.94 - - - 15,960,896 $ 0.04 5.97 12,080,205 $ 0.01 6.20
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]	Number Amount of Shares Balance, December 31, 2013 13,209 $ 2,454,192 Issued for cash pursuant to share subscriptions 183 310,977 Balance, December 31, 2014 13,392 2,765,169 Issued for cash pursuant to share subscriptions 730 1,241,171 Shares issued to settle inter-company debts 203 345,198 Share subscription receivable (313 ) (532,084 ) Balance, December 31, 2015 14,012 3,819,454 Shares issued to settle inter-company debts 1,051 1,786,656 Balance, December 31, 2016 15,063 $ 5,606,110

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	For the year ended For the year ended December 31, 2016 December 31, 2015 $ $ Net loss before taxes (2,232,021 ) (2,589,234 ) Statutory tax rate 34% 34% Income tax recovery (758,887 ) (880,340 ) Non-deductible item 77,623 131,208 Change in estimates - (515,645 ) Change enacted tax rate - 20,367 Foreign tax rate difference 122,231 142,616 Discount on convertible debenture - 289,824 Change in valuation allowance 559,033 811,970 Income tax expense (recovery) - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2016 December 31, 2015 $ $ Loss carry forwards 3,811,063 3,312,236 Convertible debenture (148,971 ) (209,177 ) Valuation allowance (3,662,092 ) (3,103,059 ) Deferred tax assets - -
Schedule of deferred tax asset attributable to net operating loss carry forwards [Table Text Block]	Year Total 2029 $ 3,163 2030 69,495 2031 98,143 2032 4,426,198 2033 1,019,303 2034 1,186,199 2035 553,916 2036 555,992 $ 7,912,409

Commitments And Guarantees (Tab

Commitments And Guarantees (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Consulting fee and Year Salaries Office rent Total 2017 $ 312,272 $ 37,824 $ 350,096 2018 - 22,064 22,064 Total $ 312,272 $ 59,888 $ 372,160

Geographic Information (Tables)

Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Long-lived Assets by Geographic Areas [Table Text Block]	Year ended December 31, 2016 US Israel Total Long-live assets $ - $ 55,444 $ 55,444	Year ended December 31, 2015 US Israel Total Long-live assets $ - $ 58,321 $ 58,321

Supplemental Disclosure with 28

Supplemental Disclosure with Respect to Cash Flows (Tables)	12 Months Ended
	Dec. 31, 2016
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	December 31, 2016 December 31, 2015 $ $ Convertible debentures issued for debt 172,894 1,040,503

Nature of Operations and goin29

Nature of Operations and going concern (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)shares
Nature Of Operations And Going Concern 1	100.00%
Nature Of Operations And Going Concern 2 | shares	16,000,000
Nature Of Operations And Going Concern 3	89.00%
Nature Of Operations And Going Concern 4	$ 10
Nature Of Operations And Going Concern 5	430
Nature Of Operations And Going Concern 6	305,964
Nature Of Operations And Going Concern 7	1,104,876
Nature Of Operations And Going Concern 8	$ 9,982,269

Significant Accounting Polici30

Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)yr
Significant Accounting Policies 1	86.13%
Significant Accounting Policies 2	2015.00%
Significant Accounting Policies 3 | $	$ 540
Significant Accounting Policies 4	3
Significant Accounting Policies 5 | yr	15

License and Research Funding 31

License and Research Funding Agreement (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)d$ / sharesshares
License And Research Funding Agreement 1	$ 1,600,000
License And Research Funding Agreement 2	$ 81,000
License And Research Funding Agreement 3 | d	5
License And Research Funding Agreement 4	$ 359,500
License And Research Funding Agreement 5	359,500
License And Research Funding Agreement 6	400,000
License And Research Funding Agreement 7	$ 400,000
License And Research Funding Agreement 8	15.00%
License And Research Funding Agreement 9	1,765
License And Research Funding Agreement 10	$ 1,698.97
License And Research Funding Agreement 11	$ 2,998,682
License And Research Funding Agreement 12 | shares	1,765
License And Research Funding Agreement 13 | $ / shares	$ 1,698.97
License And Research Funding Agreement 14	$ 1,327,758
License And Research Funding Agreement 15	$ 1,615,745

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)shares
Related Party Transactions 1	$ 581,943
Related Party Transactions 2	538,072
Related Party Transactions 3	108,000
Related Party Transactions 4	108,000
Related Party Transactions 5	$ 6,300
Related Party Transactions 6	0
Related Party Transactions 7	$ 34,609
Related Party Transactions 8	16,325
Related Party Transactions 9	172,895
Related Party Transactions 10	$ 74,062
Related Party Transactions 11	10.00%
Related Party Transactions 12	$ 74,062
Related Party Transactions 13 | shares	462,890
Related Party Transactions 14	$ 0.16
Related Party Transactions 15	$ 36,987

Convertible debentures (Narrati

Convertible debentures (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Convertible Debentures 1	$ 852,418
Convertible Debentures 2	0.055
Convertible Debentures 3	188,085
Convertible Debentures 4	0.20
Convertible Debentures 5	172,895
Convertible Debentures 6	0.20
Convertible Debentures 7	$ 852,418
Convertible Debentures 8	77.00%
Convertible Debentures 9	$ 368,496
Convertible Debentures 10	$ 192,114

Equity (Narrative) (Details)

Equity (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)yr$ / sharesshares
Equity 1 | shares	500,000,000
Equity 2 | $ / shares	$ 0.001
Equity 3 | shares	3,550,000
Equity 4 | $ / shares	$ 0.20
Equity 5	$ 710,000
Equity 6 | shares	500,000
Equity 7 | $ / shares	$ 0.20
Equity 8	$ 100,000
Equity 9	$ 74,062
Equity 10 | shares	462,890
Equity 11 | $ / shares	$ 0.20
Equity 12 | shares	481,179
Equity 13 | $ / shares	$ 0.01
Equity 14	$ 4,812
Equity 15 | shares	100,000
Equity 16 | $ / shares	$ 0.01
Equity 17	$ 1,000
Equity 18 | shares	5,000,000
Equity 19 | $ / shares	$ 0.20
Equity 20	$ 1,000,000
Equity 21 | shares	3,824,922
Equity 22 | $ / shares	$ 0.16
Equity 23	80.00%
Equity 24	$ 611,987
Equity 25 | shares	1,786,250
Equity 26 | $ / shares	$ 0.16
Equity 27	80.00%
Equity 28	$ 285,800
Equity 29 | shares	637,500
Equity 30 | $ / shares	$ 0.16
Equity 31	80.00%
Equity 32	$ 102,000
Equity 33 | shares	1,756,619
Equity 34 | $ / shares	$ 0.16
Equity 35	80.00%
Equity 36	$ 281,059
Equity 37 | shares	2,198,819
Equity 38 | $ / shares	$ 0.16
Equity 39	80.00%
Equity 40	$ 351,811
Equity 41 | shares	318,742
Equity 42 | $ / shares	$ 0.16
Equity 43	80.00%
Equity 44	$ 50,999
Equity 45 | shares	625,000
Equity 46 | $ / shares	$ 0.20
Equity 47	$ 125,000
Equity 48 | shares	824,992
Equity 49 | $ / shares	$ 0.16
Equity 50	80.00%
Equity 51	$ 131,999
Equity 52 | shares	318,749
Equity 53 | $ / shares	$ 0.16
Equity 54	80.00%
Equity 55	$ 50,999
Equity 56 | shares	1,115,625
Equity 57 | $ / shares	$ 0.16
Equity 58	80.00%
Equity 59	$ 178,500
Equity 60 | shares	2,500,000
Equity 61 | $ / shares	$ 0.20
Equity 62	$ 500,000
Equity 63 | shares	50,000
Equity 64 | $ / shares	$ 0.01
Equity 65	$ 500
Equity 66 | shares	839,375
Equity 67 | $ / shares	$ 0.16
Equity 68	80.00%
Equity 69	$ 134,300
Equity 70 | shares	4,653,732
Equity 71 | $ / shares	$ 0.16
Equity 72	80.00%
Equity 73	$ 744,597
Equity 74	0
Equity 75	15,000
Equity 76	$ 158,750
Equity 77 | shares	793,750
Equity 78 | shares	114,180,828
Equity 79 | shares	20,000,000
Equity 80 | $ / shares	$ 0.001
Equity 81 | shares	962,358
Equity 82 | $ / shares	$ 0.01
Equity 83	481,179
Equity 84 | $ / shares	$ 0.01
Equity 85	$ 4,812
Equity 86	17,628
Equity 87	$ 112,888
Equity 88 | shares	800,000
Equity 89 | $ / shares	$ 0.01
Equity 90	480,000
Equity 91 | shares	320,000
Equity 92	600
Equity 93 | yr	4
Equity 94	50
Equity 95	$ 28,419
Equity 96	$ 72,453
Equity 97 | shares	1,924,717
Equity 98 | $ / shares	$ 0.01
Equity 99	$ 26,364
Equity 100	$ 154,271
Equity 101 | shares	500,000
Equity 102 | $ / shares	$ 0.01
Equity 103	$ 10,585
Equity 104	$ 52,865
Equity 105 | shares	150,000
Equity 106 | $ / shares	$ 0.01
Equity 107	$ 208
Equity 108	$ 982
Equity 109 | shares	150,000
Equity 110 | $ / shares	$ 0.01
Equity 111	25,000
Equity 112	75,000
Equity 113	50,000
Equity 114	$ 12
Equity 115	$ 24,016
Equity 116	100,000
Equity 117 | $ / shares	$ 0.01
Equity 118	$ 1,000
Equity 119 | shares	150,000
Equity 120 | $ / shares	$ 0.20
Equity 121	$ 9,347
Equity 122	$ 5,413
Equity 123 | shares	1,730,000
Equity 124 | $ / shares	$ 0.20
Equity 125	$ 107,843
Equity 126	$ 53,701
Equity 127 | shares	150,000
Equity 128 | $ / shares	$ 0.20
Equity 129	$ 12,098
Equity 130	$ 4,879
Equity 131 | shares	50,000
Equity 132 | $ / shares	$ 0.20
Equity 133	$ 4,482
Equity 134	$ 500
Equity 135 | shares	125,000
Equity 136 | $ / shares	$ 0.20
Equity 137	$ 11,393
Equity 138	$ 978
Equity 139 | shares	100,000
Equity 140 | $ / shares	$ 0.20
Equity 141	$ 9,436
Equity 142 | shares	50,000
Equity 143 | $ / shares	$ 0.20
Equity 144	$ 2,894
Equity 145 | shares	75,000
Equity 146 | $ / shares	$ 0.20
Equity 147	$ 4,425
Equity 148 | shares	150,000
Equity 149 | $ / shares	$ 0.20
Equity 150	$ 13,385
Equity 151 | shares	800,000
Equity 152 | $ / shares	$ 0.20
Equity 153	480,000
Equity 154 | shares	320,000
Equity 155	600
Equity 156 | yr	4
Equity 157	50
Equity 158	$ 23,746
Equity 159 | shares	360,000
Equity 160 | $ / shares	$ 0.20
Equity 161	$ 29,946
Equity 162 | shares	1,765
Equity 163	15.00%
Equity 164 | shares	592
Equity 165 | $ / shares	$ 1,698.97
Equity 166	4.79%
Equity 167	$ 1,005,795
Equity 168	80.00%
Equity 169	$ 500,000
Equity 170	$ 30,000,000
Equity 171 | shares	684
Equity 172 | $ / shares	$ 1,698.97
Equity 173	5.11%
Equity 174	$ 1,162,192
Equity 175 | shares	760
Equity 176 | $ / shares	$ 1,700
Equity 177	5.68%
Equity 178	$ 1,292,000
Equity 179 | shares	183
Equity 180 | $ / shares	$ 1,699
Equity 181	1.37%
Equity 182	$ 310,977
Equity 183 | shares	417
Equity 184 | $ / shares	$ 1,700
Equity 185	$ 709,087
Equity 186 | shares	516
Equity 187	$ 1,700
Equity 188	$ 532,084
Equity 189 | shares	588
Equity 190	6,248,672
Equity 191	77.00%
Equity 192	12.60%
Equity 193	10.40%
Equity 194	2014.00%
Equity 195	13.18%
Equity 196	12.15%
Equity 197 | shares	1,132
Equity 198	12,026,654
Equity 199	$ 1,786,656
Equity 200 | shares	1,051
Equity 201	86.13%
Equity 202	11.72%
Equity 203	2.15%
Equity 204	2015.00%
Equity 205	12.60%
Equity 206	10.40%
Equity 207	2,152,695
Equity 208 | shares	1,765
Equity 209 | $ / shares	$ 1,698.97

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Taxes 1	$ 7,912,409
Income Taxes 2	7,356,417
Income Taxes 3	4,483,377
Income Taxes 4	$ 3,244,221

Commitments And Guarantees (Nar

Commitments And Guarantees (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)yrshares
Commitments And Guarantees 1	$ 250,000
Commitments And Guarantees 2 | shares	3,750,000
Commitments And Guarantees 3	$ 0.01
Commitments And Guarantees 4 | yr	10
Commitments And Guarantees 5	$ 112,324
Commitments And Guarantees 6	432,000
Commitments And Guarantees 7 | shares	2,750,000
Commitments And Guarantees 8	$ 0.01
Commitments And Guarantees 9 | yr	10
Commitments And Guarantees 10	$ 106,084
Commitments And Guarantees 11	408,000
Commitments And Guarantees 12 | shares	2,000,000
Commitments And Guarantees 13	$ 0.01
Commitments And Guarantees 14 | yr	10
Commitments And Guarantees 15 | yr	2
Commitments And Guarantees 16	$ 3,152
Commitments And Guarantees 17	12,121
Commitments And Guarantees 18	$ 59,888
Commitments And Guarantees 19	339,388
Commitments And Guarantees 20	$ 13,254
Commitments And Guarantees 21	50,000

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016USD ($)shares
Subsequent Events 1 | $	$ 30,000
Subsequent Events 2 | shares	150,000
Subsequent Events 3 | $	$ 50,000
Subsequent Events 4 | shares	250,000

Schedule of Research and Develo

Schedule of Research and Development Costs (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Significant Accounting Policies Schedule Of Research And Development Costs 1	$ 84,013
Significant Accounting Policies Schedule Of Research And Development Costs 2	17,755
Significant Accounting Policies Schedule Of Research And Development Costs 3	15,221
Significant Accounting Policies Schedule Of Research And Development Costs 4	7,760
Significant Accounting Policies Schedule Of Research And Development Costs 5	15,548
Significant Accounting Policies Schedule Of Research And Development Costs 6	7,757
Significant Accounting Policies Schedule Of Research And Development Costs 7	739,500
Significant Accounting Policies Schedule Of Research And Development Costs 8	459,498
Significant Accounting Policies Schedule Of Research And Development Costs 9	132,207
Significant Accounting Policies Schedule Of Research And Development Costs 10	617,613
Significant Accounting Policies Schedule Of Research And Development Costs 11	29,082
Significant Accounting Policies Schedule Of Research And Development Costs 12	8,820
Significant Accounting Policies Schedule Of Research And Development Costs 13	312,187
Significant Accounting Policies Schedule Of Research And Development Costs 14	486,591
Significant Accounting Policies Schedule Of Research And Development Costs 15	1,327,758
Significant Accounting Policies Schedule Of Research And Development Costs 16	$ 1,615,745

Schedule of Properties Estimate

Schedule of Properties Estimated Useful life (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Significant Accounting Policies Schedule Of Properties Estimated Useful Life 1	$ 15
Significant Accounting Policies Schedule Of Properties Estimated Useful Life 2	3
Significant Accounting Policies Schedule Of Properties Estimated Useful Life 3	4
Significant Accounting Policies Schedule Of Properties Estimated Useful Life 4	3
Significant Accounting Policies Schedule Of Properties Estimated Useful Life 5	$ 15

Schedule of Property, Plant and

Schedule of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 1	$ 1,637
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 2	19,117
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 3	43,759
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 4	64,513
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 5	1,859
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 6	7,372
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 7	673
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 8	9,904
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 9	3,496
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 10	26,489
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 11	44,432
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 12	74,417
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 13	0
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 14	3,769
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 15	2,423
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 16	6,192
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 17	94
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 18	6,876
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 19	5,811
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 20	12,781
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 21	94
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 22	10,645
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 23	8,234
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 24	18,973
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 25	1,637
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 26	15,348
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 27	41,336
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 28	58,321
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 29	3,402
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 30	15,844
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 31	36,198
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 32	$ 55,444

Schedule of Convertible Debt (D

Schedule of Convertible Debt (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Convertible Debentures Schedule Of Convertible Debt 1	$ 1,040,503
Convertible Debentures Schedule Of Convertible Debt 2	172,894
Convertible Debentures Schedule Of Convertible Debt 3	1,213,397
Convertible Debentures Schedule Of Convertible Debt 4	(852,418)
Convertible Debentures Schedule Of Convertible Debt 5	0
Convertible Debentures Schedule Of Convertible Debt 6	(852,418)
Convertible Debentures Schedule Of Convertible Debt 7	188,085
Convertible Debentures Schedule Of Convertible Debt 8	172,894
Convertible Debentures Schedule Of Convertible Debt 9	360,979
Convertible Debentures Schedule Of Convertible Debt 10	192,114
Convertible Debentures Schedule Of Convertible Debt 11	176,382
Convertible Debentures Schedule Of Convertible Debt 12	368,496
Convertible Debentures Schedule Of Convertible Debt 13	380,199
Convertible Debentures Schedule Of Convertible Debt 14	349,276
Convertible Debentures Schedule Of Convertible Debt 15	$ 729,475

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	$ 3
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	10
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	3
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	$ 7
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	0.73
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	2.45%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	0.97
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	2.09%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	65.99
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	99.04%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	62.86
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	94.97%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13	0.00%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14	0.00%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 15	0.00%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 16	0.00%

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 1	$ 14,237,075
Equity Schedule Of Share-based Compensation, Stock Options, Activity 2	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 3	$ (481,179)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 4	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 5	$ (100,000)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 6	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 7	$ 150,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 8	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 9	$ 1,610,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 10	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 11	$ 120,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 12	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 13	$ 150,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 14	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 15	$ 50,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 16	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 17	$ 125,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 18	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 19	$ 100,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 20	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 21	$ 15,960,896
Equity Schedule Of Share-based Compensation, Stock Options, Activity 22	0.04
Equity Schedule Of Share-based Compensation, Stock Options, Activity 23	$ 50,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 24	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 25	$ 75,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 26	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 27	$ 150,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 28	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 29	$ 800,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 30	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 31	$ (50,000)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 32	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 33	$ 360,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 34	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 35	$ 17,345,896
Equity Schedule Of Share-based Compensation, Stock Options, Activity 36	0.05

Schedule of Disclosure of Share

Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	12 Months Ended
	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4	5.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	5.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9	$ 481,179
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	1.41
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	$ 240,589
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14	1.41
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	$ 800,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18	1.64
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19	$ 680,001
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	1.64
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23	$ 1,924,717
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	3.87
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	$ 1,924,717
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28	3.87
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	$ 500,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	2
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33	$ 500,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	2
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39	4.34
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40	$ 100,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42	4.34
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46	4.34
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49	4.34
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51	$ 120,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53	5.65
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54	$ 40,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56	5.65
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58	$ 1,610,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60	5.60
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61	$ 536,667
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63	5.60
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67	5.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68	$ 100,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70	5.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74	5.90
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75	$ 16,667
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77	5.90
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 78	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 79	$ 125,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 80	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 81	5.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 82	$ 41,667
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 83	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 84	5.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 85	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 86	$ 100,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 87	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 88	5.93
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 89	$ 33,333
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 90	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 91	5.93
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 92	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 93	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 94	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 95	6.13
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 96	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 97	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 98	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 99	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 100	$ 75,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 101	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 102	6.18
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 103	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 104	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 105	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 106	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 107	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 108	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 109	9.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 110	$ 30,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 111	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 112	9.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 113	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 114	$ 800,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 115	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 116	4.43
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 117	$ 26,667
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 118	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 119	4.43
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 120	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 121	$ 360,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 122	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 123	6.84
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 124	$ 180,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 125	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 126	6.84
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 127	$ 17,345,896
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 128	0.05
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 129	5.03
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 130	$ 14,250,308
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 131	0.02
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 132	5.04
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2		$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5		$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9		$ 481,179
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11		2.41
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16		$ 800,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18		2.64
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19		$ 453,334
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21		2.64
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23		$ 1,924,717
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25		4.87
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26		$ 1,443,538
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28		4.87
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30		$ 500,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32		3.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33		$ 333,334
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35		3.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37		$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39		5.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42		5.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46		3.37
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51		$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53		5.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58		$ 120,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60		6.65
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65		$ 1,610,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67		6.61
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72		$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 78		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 79		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 80		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 81		6.90
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 82		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 83		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 84		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 85		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 86		$ 125,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 87		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 88		6.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 89		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 90		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 91		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 92		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 93		$ 100,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 94		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 95		6.94
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 96		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 97		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 98		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 99		$ 15,960,896
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 100		0.04
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 101		5.97
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 102		$ 12,080,205
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 103		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 104		6.20

Consolidation, Less than Wholly

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 1	$ 13,209
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 2	2,454,192
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 3	183
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 4	310,977
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 5	13,392
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 6	2,765,169
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 7	730
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 8	1,241,171
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 9	203
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 10	345,198
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 11	(313)
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 12	(532,084)
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 13	14,012
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 14	3,819,454
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 15	1,051
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 16	1,786,656
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 17	15,063
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 18	$ 5,606,110

Schedule of Income before Incom

Schedule of Income before Income Tax, Domestic and Foreign (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 1	$ (2,232,021)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 2	$ (2,589,234)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 3	34.00%
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 4	34.00%
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 5	$ (758,887)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 6	(880,340)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 7	77,623
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 8	131,208
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 9	0
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 10	(515,645)
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 11	0
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 12	20,367
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 13	122,231
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 14	142,616
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 15	0
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 16	289,824
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 17	559,033
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 18	811,970
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 19	0
Income Taxes Schedule Of Income Before Income Tax, Domestic And Foreign 20	$ 0

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 1	$ 3,811,063
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 2	3,312,236
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 3	(148,971)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 4	(209,177)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 5	(3,662,092)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 6	(3,103,059)
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 7	0
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 8	$ 0

Schedule of deferred tax asset

Schedule of deferred tax asset attributable to net operating loss carry forwards (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 1	$ 3,163
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 2	69,495
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 3	98,143
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 4	4,426,198
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 5	1,019,303
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 6	1,186,199
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 7	553,916
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 8	555,992
Income Taxes Schedule Of Deferred Tax Asset Attributable To Net Operating Loss Carry Forwards 9	$ 7,912,409

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments for Operating Leases (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 1	$ 312,272
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 2	37,824
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 3	350,096
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 4	0
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 5	22,064
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 6	22,064
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 7	312,272
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 8	59,888
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 9	$ 372,160

Long-lived Assets by Geographic

Long-lived Assets by Geographic Areas (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Geographic Information Long-lived Assets By Geographic Areas 1	$ 0
Geographic Information Long-lived Assets By Geographic Areas 2	55,444
Geographic Information Long-lived Assets By Geographic Areas 3	$ 55,444
Geographic Information Long-lived Assets By Geographic Areas 1		$ 0
Geographic Information Long-lived Assets By Geographic Areas 2		58,321
Geographic Information Long-lived Assets By Geographic Areas 3		$ 58,321

Schedule of Cash Flow, Suppleme

Schedule of Cash Flow, Supplemental Disclosures (Details)	12 Months Ended
	Dec. 31, 2016USD ($)
Supplemental Disclosure With Respect To Cash Flows Schedule Of Cash Flow, Supplemental Disclosures 1	$ 172,894
Supplemental Disclosure With Respect To Cash Flows Schedule Of Cash Flow, Supplemental Disclosures 2	$ 1,040,503